Regentis Biomaterials Ltd. (RGNT)
NYSE: RGNTHealth CareIndustrial SpecialtiesUSD
At close: Nov 20, 3:59 PM ET · Delayed 15 min
RGNT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.05M
- EPS (TTM)
- -$2.46
- Dividend yield
- None
- 52-week range
- 0.712 – 15.50
- Day range
- 0.7123 – 0.8889
- Volume / Avg
- 122.34K / 49.60K
- Beta
- —
- Shares outstanding
- 7.02M
52-week range
RGNT stock today
Shares of Regentis Biomaterials (RGNT) finished lower on Nov 20 at $0.7186, a drop of 14.42% or $0.1211 per share, versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 122.34K shares, a sign of unusually heavy trading. Shares are 95.4% below their 52-week high of $15.50, set on Jun 15, 2026 and 0.9% above the 52-week low of $0.712, near the bottom of the past year's range.
RGNT is down 89.3% year to date, underperforming the S&P 500 (+1.2%). Regentis Biomaterials has posted a net loss over the last twelve months (EPS of -$2.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Regentis Biomaterials
Company profileRegentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
- Sector
- Health Care
- Industry
- Industrial Specialties
- CEO
- Dr. Ehud Geller Ph.D.
- Headquarters
- Herzliya
- IPO year
- 2025
- Website
- regentis.co.il
Financial highlights
Full financialsRegentis Biomaterials reported a net loss of $13.6 million, compared with net income of $4.8 million a year earlier. Diluted earnings per share came in at -$24.16, down from $1.72.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-13.65M | $4.80M | $-4.13M |
| EPS (diluted) | $-24.16 | $1.72 | $-24.09 |
Analyst forecast
ForecastConsensus
none
Avg. price target
$10.00+1291.59%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Regentis Biomaterials peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LFWDLifeward Ltd. | 2.80 | -5.30% | $7.96M | vs RGNT |
| BBLGBone Biologics Corp | 0.2685 | -2.40% | $909.96K | vs RGNT |
| FGIFGI Industries Ltd. | 4.90 | -6.84% | $9.46M | vs RGNT |
| OPHICollPlant Biotechnologies Ltd | 3.13 | -2.49% | $9.63M | vs RGNT |
| HSCSHeartSciences Inc. | 1.81 | -10.84% | $10.42M | vs RGNT |
| CUPRCuprina Holdings (Cayman) Limited Class A | 1.41 | -6.00% | $10.79M | vs RGNT |
| TLIHTen-League International Holdings Limited | 5.79 | +0.70% | $17.03M | vs RGNT |
| MLSSMilestone Scientific Inc. | 0.24 | -0.83% | $21.75M | vs RGNT |
Indexes, lists and sector
Regentis Biomaterials stock FAQ
What is Regentis Biomaterials's stock price today?
RGNT last traded at $0.7186 as of Nov 20, 3:59 PM EST, down 14.42% on the day. Prices are delayed at least 15 minutes.
Who is Regentis Biomaterials's CEO?
Dr. Ehud Geller Ph.D. is the chief executive officer of Regentis Biomaterials Ltd..
What is the RGNT 52-week high?
The 52-week high for RGNT is $15.50 and the 52-week low is $0.712. The stock is currently 95.4% below its high.